GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Debt-to-Equity

CTOR (Citius Oncology) Debt-to-Equity : 0.08 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Debt-to-Equity?

Citius Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Citius Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.80 Mil. Citius Oncology's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $46.14 Mil. Citius Oncology's debt to equity for the quarter that ended in Sep. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Citius Oncology's Debt-to-Equity or its related term are showing as below:

CTOR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08   Med: 0.08   Max: 0.08
Current: 0.08

During the past 3 years, the highest Debt-to-Equity Ratio of Citius Oncology was 0.08. The lowest was 0.08. And the median was 0.08.

CTOR's Debt-to-Equity is ranked better than
74.36% of 815 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs CTOR: 0.08

Citius Oncology Debt-to-Equity Historical Data

The historical data trend for Citius Oncology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Debt-to-Equity Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Debt-to-Equity
- - 0.08

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Debt-to-Equity - - 0.08

Competitive Comparison of Citius Oncology's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Debt-to-Equity falls into.


;
;

Citius Oncology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Citius Oncology's Debt to Equity Ratio for the fiscal year that ended in Sep. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 3.8) / 46.14
=0.08

Citius Oncology's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 3.8) / 46.14
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology  (NAS:CTOR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Citius Oncology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Debt-to-Equity
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.